Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826742 · ClinicalTrials.gov registry record · Phase 4
Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT06826742: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT06826742 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06826742, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.
Primary Outcome
Total opioid consumption of either intrathecal opiate or intravenous methadone at 24-48 hours after delivery.
Interventions
- DRUG Intrathecal Morphine
- DRUG Intravenous line (IV) Methadone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2025-09-23 |
| Phase | Phase 4 |
What the finished NCT06826742 record still lists
NCT06826742 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Intrathecal Morphine is the first listed.
NCT06826742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06826742 about?
NCT06826742 is a clinical study titled "Intravenous Methadone Versus Intrathecal Morphine for Analgesia Following Cesarean Delivery". The purpose of this study is to determine if there is a difference in opioid requirements at 0-48 hours after scheduled cesarean delivery in patients receiving 150 mcg intrathecal morphine compared to 0.2 mg/kg (maximum 20 mg) intravenous methadone.
What is the current status of trial NCT06826742?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-02-12. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT06826742?
The interventions under investigation include: Intrathecal Morphine (DRUG), Intravenous line (IV) Methadone (DRUG).
Who is sponsoring clinical trial NCT06826742?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06826742's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI